Citigroup Initiates Coverage On Celldex Therapeutics with Buy Rating, Announces Price Target of $70
Portfolio Pulse from Benzinga Newsdesk
Citigroup has initiated coverage on Celldex Therapeutics with a Buy rating and set a price target of $70.
October 07, 2024 | 3:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Citigroup analyst David Lebowitz has initiated coverage on Celldex Therapeutics with a Buy rating and a price target of $70, indicating a positive outlook for the stock.
The initiation of coverage with a Buy rating and a specific price target of $70 by a major financial institution like Citigroup is likely to positively influence investor sentiment and could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100